Dorfman Mizrach & Thaler

Dorfman Mizrach & Thaler

Founded in 1937, Dorfman Mizrach & Thaler operates as a single-family office built atop an active accounting practice in Iselin, New Jersey. The firm's contemporary leadership traces through Howard Dorfman, an attorney whose career included roles as Vice President and General Counsel at Ferring Pharmaceuticals, chief legal officer of Bayer Healthcare's pharmaceutical division, and counsel at Bristol-Myers Squibb and Ropes & Gray. That deep pharmaceutical legal pedigree — rather than a disclosed operating-company exit — informs the office's concentrated investment lens in healthcare services and life sciences. DMT pursues direct investments across venture capital, growth equity, and buyout stages, alongside allocations to real estate and infrastructure. The firm's active investment types span private equity, startups, and philanthropic or mission-related vehicles. Confirmed positions include the firm's stewardship of intellectual property such as the Creativity Machine, and interests in healthcare services, industrial technology, prop-tech, media and entertainment, digital health, energy transition and renewables, and supply chain and logistics. The office deploys exclusively within North America, and its approach integrates tax and accounting infrastructure directly into deal evaluation — a structural byproduct of maintaining a licensed CPA firm. The office also advises on fiduciary services and multi-generational planning for high-net-worth families. Principals Howard Dorfman, Steven Thaler, and Michael I. Thaler extend the firm's reach through external professional platforms. Steven Thaler and Michael I. Thaler are listed as experts at Prager Metis, an international advisory and accounting firm — a relationship that embeds DMT in a broader professional-services network. Howard Dorfman is an Adjunct Professor at Seton Hall Law School and Editor of PLI's Pharmaceutical Compliance and Enforcement Answer Book, reinforcing the office's proprietary expertise in life-sciences regulatory strategy. The firm also maintains relationships with family-asset entities such as U S H T LTD, for which DMT serves as a registered address. No capital-formation events or senior hires were publicly disclosed in the last 24 months. The office's distinct architecture is its dual identity as both a licensed CPA firm and a family investment office. That structure allows deal sourcing and due diligence to run through a tax-and-compliance-native lens — a posture that is atypical for single-family offices and material when evaluating regulatory-heavy sectors like pharmaceuticals, healthcare compliance, and industrial technology. The firm does not market itself as a capital allocator to external limited partners; its capital base remains undisclosed and appears to derive from internal family wealth managed through the accounting-and-legal infrastructure of the firm itself.